Under construction – not a live service
Sign in
Enrolling by invitationNo phase

Checks a glucose monitoring device in people with diabetes

Studies a CT3 glucose monitor worn for 14 days by adults with diabetes.

Key facts

Who runs it
MDCECRO LLC
Where
Riga, LatviaSee the site
Trial code
Registry title
Post-Market Clinical Follow-Up of the CT3 Series Continuous Glucose Monitoring System: A 14-Day Observational Study Assessing Accuracy, Safety, and Glucose Control in Patients With Type 1 and Type 2 Diabetes Mellitus
Status
Enrolling by invitation
People taking part
72 people, planned
Started
4 Jun 2025
Planned end
31 Jan 2026
Type of study
Observational
Treatments tested
  • CT3 Series Continuous Glucose Monitoring System:
Record updated
22 August 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 1 or type 2 diabetes. They wear a continuous glucose monitoring system for 14 days.

Age
18 to 80 years
Sex
All sexes can join.
Disease stage
Type 1 or type 2 diabetes mellitus.
Earlier treatment
People who took part in a drug or device trial within 1 month cannot join.

Main reasons for not taking part

  • Broken, scarred, red, swollen or infected skin on the upper arms or abdomen
  • Allergy to alcohol disinfectants or medical adhesive tapes
  • Blood disease affecting clotting, bleeding tendency, anemia or abnormal hematocrit
  • Pregnant or breastfeeding women
  • Planned MRI, CT or X-ray within 14 days of wearing the device

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • 1.Patients diagnosed with type 1 or 2 diabetes mellitus. 2.People aged 18 years or older, regardless of gender. 3.Those who sign informed consent to participate in this study voluntarily. 4.The patient had good compliance and could complete this whole clinical investigation

Who cannot take part

  • 1.Those who have broken, scarred, red, swollen, or infected skin on the upper arms or abdomen; 2.Those who are allergic to alcohol disinfectants or medical adhesive tapes. 3.Those who have hematologic diseases that affect coagulation function or have been diagnosed with a bleeding tendency; 4.Those who have anemia or abnormal hematocrit. 5.Pregnant and lactating women. 6.Psychiatric abnormalities, cognitive and communication disorders, or highly stressed and uncooperative; 7.Those with subcutaneous edema at the wearing site. 8. Those who plan to undergo magnetic resonance imaging (MRI), computed tomography (CT), or X-ray examination within 14 days of wearing; Those who have participated in clinical trials of drugs or devices within 1 month; 10.Those who are considered by the investigator to be inappropriate to participate in this PMCF study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in Latvia

  • Paula Stradiņa Klīniskā Universitātes SlimnīcaRiga, LatviaNo longer taking part

About the trial

What the trial wants to find out

Post market Clinical follow-up of the CT3 Series Continuous Glucose Monitoring System: A 14-Day Observational Study Assessing Accuracy, Safety, and Glucose Control in patients with Type 1 and Type 2 Diabetes Mellitus

Treatments tested

  • CT3 Series Continuous Glucose Monitoring System:

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Post-Market Clinical Follow-Up of the CT3 Series Continuous Glucose Monitoring System: A 14-Day Observational Study Assessing Accuracy, Safety, and Glucose Control in Patients With Type 1 and Type 2 Diabetes Mellitus
Plain-language title
Checks a glucose monitoring device in people with diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07122180, who can take part
Record updated
22 August 2025